Efficacy of darbepoetin alfa in chemotherapy-induced anemia in gastrointestinal cancers.

被引：0
|
作者：
Blayney, D
Vadhan-Raj, S
Tomita, D
Rossi, G
Mirtsching, B
机构：
[1] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Ctr Oncol Res & Treatment, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：781S / 781S
页数：1
相关论文
共 50 条
  • [41] Clinical benefits and risks associated with darbepoetin alfa and epoetin alfa treatment in patients with lung cancer and chemotherapy-induced anemia.
    Tiotiu, Angelica
    Clerc-Urmes, Isabelle
    Chabot, Francois
    Martinet, Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Real-life efficacy of an epoetin alfa biosimilar in chemotherapy-induced anemia
    Scotte, F.
    Laribi, K.
    Gisselbrecht, C.
    Spaeth, D.
    Kasdaghli, E.
    Leutenegger, E.
    Ray-Coquard, I.
    Albrand, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 112 - 112
  • [43] A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
    Schwartzberg, L
    Shiffman, R
    Tomita, D
    Stolshek, B
    Rossi, G
    Adamson, R
    CLINICAL THERAPEUTICS, 2003, 25 (11) : 2781 - 2796
  • [44] First comparison of biosimilar epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-induced anaemia
    Lorenz, A.
    Heine, O.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S295 - S295
  • [45] Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia
    Boccia, R
    Liu, D
    Silberstein, P
    Tschekmedyian, NS
    Holladay, C
    Tomita, D
    Rossi, G
    Otterson, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 761S - 761S
  • [46] Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP
    Pettengell, Ruth
    Salar Silvestre, Antonio
    Schwenkglenks, Matthias
    Rossi, Francesca Gaia
    Duehrsen, Ulrich
    Verhoef, Gregor
    Lugtenburg, Pieternella Johanna
    Wheeler, Tracey
    Pujol, Beatriz
    Haioun, Corinne
    HEMATOLOGY, 2013, 18 (01) : 26 - 29
  • [47] Epoetin Alfa and Darbepoetin Alfa in Clinical Practice in Patients With Chemotherapy Induced Anemia in the Netherlands (EVALUATE)
    van Groeningen, C. J.
    Kok, T. C.
    Biesma, B.
    Melissant, C. F.
    de Klerk, G.
    Brok, R. G. P. M.
    Lahaye, M.
    Milek, R. L. B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S237 - S237
  • [48] Incremental cost-effectiveness ratio of darbepoetin alfa (Aranesp®) in the treatment of chemotherapy-induced anemia in lung cancer patients
    Borget, I
    Tilleul, P.
    Joly, A. C.
    Chouaid, C.
    VALUE IN HEALTH, 2006, 9 (06) : A278 - A279
  • [49] Phase II trial comparing darbepoetin alfa every 3-week versus weekly epoetin alfa for the treatment of chemotherapy-induced anemia
    Hassan, M. A.
    Sleem, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe
    Deger, Melike
    Eisterer, Wolfgang
    Kutikova, Lucie
    Salek, Sam
    SUPPORTIVE CARE IN CANCER, 2013, 21 (02) : 485 - 493
12345